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Large animal studies are required to
assess the potential of human pluripotent
stem cell (hPSC)-derived cells for cardiac
repair. Ye et al. show that engraftment of
hiPSC-derived cardiomyocytes, endo-
thelial cells, and smooth muscle cells
into a porcine model of myocardial infarc-
tion improves heart function and meta-
bolism without inducing ventricular
arrhythmias.
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Human induced pluripotent stem cells (hiPSCs) hold
promise for myocardial repair following injury, but
preclinical studies in large animal models are
required to determine optimal cell preparation and
delivery strategies to maximize functional benefits
and to evaluate safety. Here, we utilized a porcine
model of acute myocardial infarction (MI) to in-
vestigate the functional impact of intramyocardial
transplantation of hiPSC-derived cardiomyocytes,
endothelial cells, and smooth muscle cells, in combi-
nation with a 3D fibrin patch loaded with insulin
growth factor (IGF)-encapsulated microspheres.
hiPSC-derived cardiomyocytes integrated into host
myocardium and generated organized sarcomeric
structures, and endothelial and smooth muscle cells
contributed to host vasculature. Trilineage cell trans-
plantation significantly improved left ventricular
function, myocardial metabolism, and arteriole den-
sity, while reducing infarct size, ventricular wall
stress, and apoptosis without inducing ventricular
arrhythmias. These findings in a large animal MI
model highlight the potential of utilizing hiPSC-
derived cells for cardiac repair.
INTRODUCTION
Human induced pluripotent stem cells (hiPSCs) are promising
therapeutic agents that can potentially generate an unlimited
range and quantity of clinically relevant cell types that are not re-
jected by the patient’s immune system. Several studies have re-
ported generation of cardiomyocytes from hiPSCs (Burridge750 Cell Stem Cell 15, 750–761, December 4, 2014 ª2014 Elsevier Inet al., 2012), and transplantation of these cells into rodent
models of MI have suggested that they may provide functional
benefit (Caspi et al., 2007; Laflamme et al., 2007; Shiba et al.,
2012; van Laake et al., 2008). In a guinea pig model of cardiac
injury, transplanted human embryonic stem cell-derived cardio-
myocytes (hESC-CMs) showed electric coupling to native
myocardium (Shiba et al., 2012). However, preclinical studies
in large animal models of MI are necessary to fully evaluate the
therapeutic potential of this approach and to empirically deter-
mine the optimal combination of cell types, supplementary fac-
tors, and delivery methods to maximize efficacy and stringently
assess safety (Cibelli et al., 2013). To this end, Chong et al. uti-
lized a nonhuman primate model of myocardial ischemia, inject-
ing one billion hESC-CMs into the hearts of macaques with MI
injury, and finding extensive evidence of engraftment, remuscu-
larization, and electromechanical synchronization 2 to 7 weeks
after transplantation (Chong et al., 2014). Despite these prom-
ising findings, telemetric electrocardiographic (ECG) evaluation
demonstrated ventricular arrhythmias in some treated animals,
suggesting further investigation of optimal cell quantities and de-
livery approaches is warranted.
Currently, poor engraftment of transplanted cardiomyocytes
presents a significant barrier to transplantation-based ap-
proaches for myocardial cell therapy. In vitro studies strongly
suggest that myocytes survive better when cocultured with
endothelial cells (ECs) than when cultured alone (Xiong et al.,
2012). Coadministration of ECs could enhance CM survival
and benefit left ventricular (LV) myocardial perfusion, meta-
bolism, and contractile activity through release of signaling
molecules such as nitric oxide, vascular endothelial growth
factor (VEGF), and insulin growth factor (IGF), which has also
been shown to inhibit apoptosis (Davis et al., 2006; Brutsaert,
2003; Hsieh et al., 2006). Consistent with this hypothesis, we
recently demonstrated that transplantation of hiPSC-derived
ECs (hiPSC-ECs) and smooth muscle cells (hiPSC-SMCs)
into ischemic porcine myocardial tissue contributes toc.
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mance (Xiong et al., 2012); however, myocardial repair and func-
tional improvements may be even more extensive if primary
force-producing myocardial cells are included in the population
of transplanted cells.
In the present study, we injected three hiPSC-derived cell
types (hiPSC-CMs, hiPSC-ECs, and hiPSC-SMCs) directly into
injured hearts in a porcine large animal model of acute myocar-
dial infarction. Cells were coinjected through an epicardial fibrin
patch that provided prolonged release of the prosurvival factor
insulin-like growth factor 1 (IGF-1), and cell engraftment and
functional outcomes were evaluated. Our results show engraft-
ment of cells from all three lineages at the site of injury, for at least
4 weeks after injection. This was accompanied by improvements
in myocardial wall stress, metabolism, and contractile perfor-
mance, and, importantly, did not lead to the development of
ventricular arrhythmias. Together, these findings show that
coadministration of multiple hiPSC-cardiovascular lineage cell
populations promotes myocardial repair in large-animal models
of MI.
RESULTS
Differentiation of hiPSCs into Cardiac-Lineage CMs,
ECs, and SMCs
hiPSCs were reprogrammed from human dermal fibroblasts and
engineered to express eGFP (Figure S1 available online) and
differentiated into CMs via the Sandwich method (Zhang et al.,
2012). Isolated areas of contracting cells typically appeared on
day 7 of differentiation (Movies S1, S2, and S3) and were
collected 1 week later for purification via a microdissection and
preplating method. Expression of cardiac-specific proteins in
differentiated hiPSC-CMs was evaluated on day 30 after cells
started contracting. Nearly all hiPSC-CMs expressed slow
myosin heavy chain, a-sarcomeric actin (Figure 1A), and the car-
diac-specific myofilament cTnT (Figure 1B). Approximately
20%–30% of the hiPSC-CMs expressed the 2v isoform of
myosin light chain (MLC2v) (Figure 1B, middle), which is found
only in ventricular CMs, and cardiac connexin-43 was present
at numerous points of contact between adjacent cells (Fig-
ure 1C). The purity of the final hiPSC-CM population was as
high as 93% when evaluated via flow cytometry analysis of
cTnT expression (Figures 1D and 1E) and >90%when evaluated
via fluorescence immunostaining for cTnT expression (Figure 1F).
hiPSC-ECs and hiPSC-SMCs were generated via established
differentiation protocols (Hill et al., 2010; Woll et al., 2008) and
expressed EC- and SMC-specific proteins (Figures 1G–1L).
hiPSC-Derived Cardiac Cells Engraft and Survive after
Transplantation into a Porcine Model of Myocardial
Infarction
We then tested our hypothesis that transplantation of three
hiPSC-derived cardiac cell types would improve recovery after
ischemic myocardial injury in a large-animal model (swine) of
ischemia-reperfusion (IR) injury. A total of 92 pigs underwent
the IR protocol; 89 pigs survived and were divided into five
groups (Table S1). Animals receiving CMs, EC, and SMCs
(Cell group) or CMs, ECs, SMC, and the fibrin/IGF-1 patch
(Cell+Patch group) were injected with two million hiPSC-CMs,Celltwo million hiPSC-ECs, and two million hiPSC-SMCs (six million
cells total) directly into the injuredmyocardium; for animals in the
Cell+Patch group, the needle was inserted through an IGF-1-
containing fibrin scaffold patch (Figure S2) that had been created
over the site of injury. Animals in the Patch group were treated
with scaffold patch alone, and both the patch and the cells
were withheld from animals in the MI group. Animals in the
Sham group underwent all surgical procedures for induction of
IR injury, except for the ligation step, and recovered without
any experimental treatments.
We then evaluated the engraftment and survival rates of the
transplanted cells. Since the transplanted cells were genetically
male and engineered to express GFP, while the recipient pigs
were female, we performed quantitative PCR (qPCR) assess-
ments for the human Y chromosome. Lineages of surviving cells
were determined by staining for expression of the human-spe-
cific EC marker CD31 (hiPSC-ECs), for coexpression of GFP
and a-smooth-muscle actin (SMA) (hiPSC-SMCs), and for coex-
pression of GFP and cTnT (hiPSC-CMs).
At 4 weeks after injury, 4.2% ± 1.1% of transplanted cells sur-
vived in animals in the Cells groupwhile 8.97%± 1.8%survived in
the hearts of Cell+Patch animals. In contrast, 3.2% ± 0.4% of the
twomillion cells administered to theCMgroup survived. Substan-
tial proportions of all three transplanted cell types were observed
in Cell+Patch hearts: 27.1% ± 5% of surviving transplanted cells
were hiPSC-CMs, 34.2% ± 10% were hiPSC-ECs, and 40.5% ±
1%were hiPSC-SMCs. These observations suggest that the IGF-
1-containing fibrin patch may have substantially improved the
engraftment of all three hiPSC-derived cell lineages. Furthermore,
GFP-expressing cells were present in cardiac muscle fibers (Fig-
ures 2A), but rarely in fibers composedof porcine cardiomyocytes
(Figures S3A–S3D), suggesting that the transplanted hiPSC-CMs
may have developed into new muscle fibers rather than incorpo-
rating into existing host cardiac muscle. GFP+ cells were also
identified in capillaries and arterioles (Figures 2B and 2C),
although the proportion of vessels apparently generated directly
from transplanted cells was less than 0.1%.
Transplantation of hiPSC-Derived Cardiac Cells
Improves Cardiac Function and Bioenergetics after MI
Measurements of cardiac function were evaluated 1 and 4weeks
after injury and cell transplantation. Left-ventricular ejection frac-
tion (LVEF) was significantly better in Cell+Patch group animals
than in MI and Patch animals (Figure 3A) at 4 weeks. Systolic
thickening fractions that reflect regional myocardial contractility
were significantly greater in the infarct zone (IZ) and at the border
zone (BZ) of the infarct in hearts from Cell+Patch animals than in
MI hearts at both week 1 and week 4 time points (Figure 3B).
Infarct size was significantly smaller in Cell+Patch hearts than
in MI hearts (p < 0.05) at week 1, while the difference between
Cell+Patch and Patch hearts approached statistical significance
(p = 0.051) (Figure 3C).Measurements of regional wall stress per-
formed 4weeks after injury were significantly lower in Cell+Patch
hearts than in Patch hearts (Figure 3D). Together, these results
show that transplantation of multiple hiPSC-derived cardiac lin-
eages, in combination with IGF-1/fibrin patch, improves cardiac
function after MI.
We then determined whether these functional improvements
in Cell+Patch animals were accompanied by improvedStem Cell 15, 750–761, December 4, 2014 ª2014 Elsevier Inc. 751
(legend on next page)
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dial ATP hydrolysis rates were measured in vivo with the 31P
MRS-MST method (Xiong et al., 2013). Measurements were
performed at the BZ of the infarct under both baseline and
elevated cardiac work states in response to catecholamine
stimulation. Myocardial PCr/ATP ratios that reflect mitochon-
drial energetic efficiency, were significantly higher in animals
from the Cell+Patch group than in MI animals under baseline
conditions (Figure 3E), while the rate of ATP hydrolysis was
significantly higher in Cell+Patch group hearts than in MI and
Patch hearts during high cardiac workload (Figure 3F); mea-
surements in Patch and MI animals were similar under both
conditions. Collectively, these observations indicate that the
transplantation of hiPSC-derived cardiovascular cells improved
LV pump function and myocardial energy metabolism while
reducing infarct size.
Combined hiPSC-CM and Patch Treatment Does Not
Induce Ventricular Arrhythmias
Arrhythmogenesis is a primary risk associated with pluripotent
cell-derived CM therapy for treatment of cardiac disorders. In a
recent study, significant ventricular arrhythmias were detected
after transplantation of hESC-CMs in a nonhuman primatemodel
of MI (Chong et al., 2014). Thus, we examined whether the
hiPSC-CM patch transplantation protocol used here might be
associated with onset of cardiac arrhythmia. Ischemia-reperfu-
sion injury was induced in 16 pigs who then received the fibrin/
IGF-1 patch alone (Patch group), the patch and ten million
hiPSC-CMs (Patch+CMs), or neither experimental treatment
(Table S1). ECGs were recorded continuously for 4 weeks after-
ward using an implantable loop recorder. Severe arrhythmias
and ST elevations were observed in all animals during coronary
artery occlusion and reperfusion, but no animal in any treatment
group developed spontaneous arrhythmia during the 4-week
follow-up period. Furthermore, no evidence of ventricular tachy-
cardia (VT) or ventricular fibrillation (VF) was induced in response
to programmed electrical stimulation (PES) in hearts of Patch+
CM group animals, even when the most aggressive stimulation
protocol was applied. Thus, the combined Patch+hiPSC-CM
administration protocol used for the experiments described in
this report does not appear to impair the electromechanical sta-
bility of swine hearts.
Transplantation of hiPSC-Derived Cardiac Cells
Reduces Cardiomyocyte Apoptosis and Stimulates
Nkx2.5 Expression after IR Injury
We next assessed how Cell+Patch treatment improves cardiac
function. One possibility is through induction of cytoprotectiveFigure 1. Differentiation of Human iPSCs into Cardiomyocytes, Endoth
(A–C) hiPSCs were differentiated into CMs via the Sandwich method (Zhang et al.
expression of (A) slow myosin heavy chain (SMHC) and a-sarcomeric actin (a-S
protein myosin light chain 2v (MLC2v); and (C) cTnT and the gap-junction protein c
in the second panel of (C) is shown at higher magnification.
(D–F) The purity of the hiPSC-CMpopulation was evaluated via flow cytometry ana
by (F) immunofluorescence analysis of cardiac troponin I (cTnI) expression; nuclei
200 mm in (C) and (F). (See also Movies S1, S2, and S3.) hiPSCs were differentiated
(G–L) The lineage of the differentiated hiPSC-ECs was confirmed via the expres
entiated hiPSC-SMCs was confirmed via the expression of (J) smooth-muscle a
Magnification (G)–(L) = 2003. (See also Figure S1.)
Cellmechanisms. To evaluate this possibility, we measured
apoptosis in the hearts of animals sacrificed 3 days after IR
injury and treatment (Figures 4A–4G). At the BZ of the infarct,
apoptotic (i.e., TUNEL+) cells were significantly less common in
animals from the Cell+Patch group than inMI and Patch animals,
both in the total cell population (Figure 4F) and specifically
among CMs (i.e., cTnI+ cells) (Figure 4G). Furthermore, the pro-
portion of CMs that expressed Nkx2.5 (Figures 4H–4N), which
has been shown to protect CMs from oxidative stress (Toko
et al., 2002), was significantly greater in Cell+Patch animals
than in MI animals at week 4 (p < 0.05), and the difference
between Cell+Patch and Patch animals approached statistical
significance (p = 0.056), at week 1 after IR injury (Figure 4N).
Nkx2.5 expression in MI hearts increased at week 4 but re-
mained significantly lower than in Cell+Patch hearts. Thus, trans-
plantation of hiPSC-derived cells increased cell survival during
the first few days after IR injury and is associated with upregula-
tion of Nkx2.5 expression. The decline in apoptosis could also
result from improvements in wall stress and decreased fibrosis.
Consistently, examination of Masson-Trichrome-stained heart
sections from animals sacrificed at week 4 showed thicker
subepicardium in the region where the patch was applied
(2.44 mm) than in animals from the Sham (0.16 mm) or MI
(0.88 mm) groups (Figure S4).
Transplantation of hiPSC-Derived Cardiac Cells
Enhance the Vasculogenic Response to IR Injury
Increased angiogenesis could also contribute to improved ven-
tricular function. We therefore assessed whether transplantation
of hiPSC-derived cardiac cells promotes angiogenesis in peri-
infarct border zone (BZ) of MI hearts. Four weeks after injury,
CD31+vascular structures and arterioles that coexpressed
CD31 and SMA were significantly greater in the BZ of Cell and
Cell+Patch hearts than in the corresponding regions of MI and
Patch hearts (Figure 5). Additionally, vascular density was
significantly greater in the CM group than in the MI group.
Thus, transplantation of the hiPSC-derived cardiac cells pro-
moted neovascularization, probably by inducing paracrine
mechanisms in recipient myocardial tissue (Table S2).
The cell and patch treatments may also have delayed the
immune response to IR injury. While infiltration of cells ex-
pressing the inflammatory marker CD11b (Figures S5A–S5F)
peaked 3 days after injury in the MI group, this was sig-
nificantly delayed in the IZ and BZ regions of hearts from
Cell+Patch animals (Figure S5G). CD11b+ cells were sig-
nificantly more common in Cell+Patch hearts than in MI
hearts at week 1 but not at week 4, while the CM, Cells,
and Patch groups showed a statistically nonsignificantelial Cells, and Smooth Muscle Cells
, 2012), and the lineage of the differentiated hiPSC-CMs was confirmed via the
A); (B) cardiac troponin T (cTnT) and the ventricular- specific cardiomyocyte
onnexin-43 (Con-43); nuclei were counterstained with DAPI. The boxed region
lysis of cTnT expression in (D) isotype controls and (E) purified hiPSC-CMs, and
were counterstained with DAPI. Scale bar represents 100 mm in (A) and (B) and
into ECs and SMCs as described previously (Hill et al., 2010; Woll et al., 2008).
sion of (G) CD31, (H) CD144, and (I) vWF-8; and (J–L) the lineage of the differ-
ctin (SMA), (K) SM22, and (L) calponin. Nuclei were counterstained with DAPI.
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Figure 2. hiPSC-Derived Cardiac Cells Engraft and Survive after
Transplantation into the Hearts of Swine with MI
(A) Engraftment of the injected cells was evaluated in sections stained for the
presenceofGFP;muscle fiberswere visualized via fluorescent immunostaining
for cTnT, and nuclei were counterstained with DAPI. The sections displayed in
the first three panels were imaged with a phase-contrast microscope.
(B) Engrafted cells were identified in arterioles via immunofluorescent staining
for the coexpression of GFP and SMA; muscle fibers were visualized via
immunofluorescent staining for cTnI and nuclei were counterstained with
DAPI.
(C) Engrafted cells were identified in blood vessels (i.e., capillaries and arte-
rioles) via immunofluorescent staining for the human-specific isoform of CD31;
muscle fibers were visualized via cTnT staining and nuclei were counterstained
with DAPI. Scale bar represents 100 mm. (See also Figure S3.)
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response following cell transplantation, possibly reducing im-
mune rejection and increasing engraftment and survival of
hiPSC-derived cells.
Paracrine Factor Release from the hiPSC-Derived Cells
This increase in angiogenesis observed after Cell+Patch treat-
ment could be due to release of paracrine factors, as suggested
by studies showing that endothelial cells promote cardiomyo-
cyte survival (Xiong et al., 2012). To determine whether hiPSC-
derived vascular cells possess cytoprotective effects similar
to those previously reported in similar cell types, we cultured
hiPSC-CMs under hypoxic conditions in media collected from
the hiPSC-derived vascular cells (i.e., conditioned media) or
with unconditioned (basal) media. hiPSC-CMs tended to shrink
when cultured with unconditioned media but not when cultured
with the conditioned media (Figures 5I and 5J). Culture in condi-
tioned media was also associated with significant declines in
hiPSC-CM apoptosis (Figures 5K, 5L, and 5N) and in the amount
of cytoplasmic leakage of lactate dehydrogenase (LDH) from
hiPSC-CMs (Figure 5M). Thus, hiPSC-derived vascular cells
appear to release paracrine factors that protect hiPSC-CMs
from hypoxic injury.
We then performed protein array analysis to identify paracrine
factors that may be responsible for these in vitro cytoprotective
effects and that might induce repair mechanisms in injured
myocardial tissue. A total of 21 factors were detected, and their
expression was confirmed in hiPSC-CMs, as well as hiPSC-
derived vascular cells (Table S2). Several of the identified factors
are known to impede apoptosis (angiogenin, angiopoietin, IL-6,
MMP-1, PDGF-BB, TIMP-1, uPAR, and VEGF), induce cell
migration or homing (angiogenin, angiopoietin, IL-8, MCP-1,
MCP-3, MMP-9, uPAR, and VEGF), and promote cell division
(angiogenin, angiopoietin, PDGF-BB, and VEGF), suggesting
multiple paracrine mechanisms through which hiPSC-ECs and
hiPSC-SMCs could promote CM survival and cardiac repair.
Myocardial Protein Expression after IR Injury and Cell
Therapy
Understanding changes in the expression profile of myocardial
proteins will help reveal the molecular mechanisms underlying
improvements in left ventricular function associated with cell
therapy. To provide further insights into these mechanisms, we
performed a quantitative proteomics analysis on LV tissues
from SHAM hearts and from MI hearts that were treated with
or without hiPSC-derived vascular cells (which have both
hiPSC-ECs and hiPSC-SMCs) after IR injury (Figure S6). We
confidently identified 66 proteins whose expression pattern
was altered in MI hearts but fully or partially restored to normal
after cell transplantation (Figure 6). Thus, the functional benefits
associated with cell therapy appear to be accompanied by a
recovery of the myocardial protein expression profile of the
recipient hearts.
DISCUSSION
The present study is among the first to evaluate the combined
administration of three hiPSC-derived cardiovascular lineage
cells in a large-animal model of ischemic myocardial injury. Ourc.
Figure 3. Transplanted hiPSC-Derived Cardiac Lineage Cells Improve Cardiac Function
(A) LV ejection fractions were evaluated at week 1 and week 4 after MI injury and treatment.
(B) LV wall systolic thickening fractions in the infarct zone (IZ) and at the border zone (BZ) of ischemia were evaluated at week 4.
(C) Infarct sizes were evaluated at week 1 and week 4 and expressed as a percentage of the LV surface area.
(D) LV wall stress in the IZ, in the BZ, and in uninjured regions of the myocardium (i.e., the remote zone [RZ]) was evaluated at week 4.
(E and F) Four weeks after MI injury and treatment, (E) PCr/ATP ratios and (F) the ATP hydrolysis rate were determined in the BZ under both baseline conditions
and after a high cardiac workload was induced via catecholamine administration; measurements were obtained via a double-saturation 31P MRS-MST protocol.
For (B), (D), (E), and (F), measurements in Sham animals were performed in regions that corresponded to the site of injury in the other experimental groups. Data
are presented as mean ± SEM, *p < 0.05 versus MI; #p < 0.05 versus Patch. (See also Figures S2 and S4 and Table S1.)
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EC injection is performed through a fibrin patch that has been
created over the injection site and contains gelatin microspheres
that release IGF-1 into the surrounding tissue, the engraftment
rate of the transplanted cells can be as high as 8.97% ± 1.8%
4 weeks after transplantation, which is 20-fold greater than
the engraftment rate observed when adult swine progenitor cells
were evaluated in the same animal model (Zeng et al., 2007). Our
results also demonstrate that the transplanted cells developed
into functioning CMs and vascular cells and that the combination
of hiPSC-CM, hiPSC-EC, and hiPSC-SMC injection with patchCellapplication led to significant improvements in LV wall stress,
infarct size, systolic thickening fraction, vascular density, and
ATP turnover rate. These findings are consistent with the
concept that the severity of LV functional decline and structural
remodeling is proportional to scar size (Pfeffer and Braunwald,
1990) and that LV dilatation and hypertrophy are exacerbated
as increases in systolic wall stress propagate from the IZ and
BZ to the adjacent myocardium (Pfeffer and Braunwald, 1990).
Previous attempts to isolate hiPSC- or hESC-derived CMs
have been only moderately successful. Xu et al. (2006) used a
method based on Percoll separation and cardiac body formationStem Cell 15, 750–761, December 4, 2014 ª2014 Elsevier Inc. 755
Figure 4. Transplantation of hiPSC-Derived Cardiac Cells Reduces Cardiomyocyte Apoptosis and Enhances Endogenous Cell Survival
(A–G) Apoptotic cells were identified in sections from the border zone of infarct in hearts from animals in the (A) MI, (B) Patch, (C) CM, (D) CM+EC+SMC, and (E)
Cell+Patch groups with the TUNEL assay. Muscle fibers were visualized via fluorescent immunostaining for cTnI, and nuclei were counterstained with DAPI; the
boxed regions toward the left of (A), (B), (C), (D), and (E) are displayed at higher magnification in the boxes at the right of the images. (F) Apoptosis was quantified
as the percentage of cells that were positive for TUNEL staining. (G) Cardiomyocyte apoptosis was quantified as the percentage of cTnI-positive cells that were
also positive for TUNEL staining.
(H–N) NkX2.5 expression was evaluated in sections from the border zone of infarct hearts that compared to Sham operated-normal hearts: (H) Sham, (I) MI,
(J) Patch, (K) CM, (L) CM+EC+SMC, and (M) Cell+Patch. The immunofluorescent staining positives with anti-Nkx2.5 antibody are shown in green; muscle
fibers were visualized via fluorescent immunostaining for cTnI, and nuclei were counterstained with DAPI. (N) The percentage of cardiomyocytes that ex-
pressed Nkx2.5 was determined at week 1 and week 4 after injury. Data are presented as mean ± SEM. *p < 0.05; scale bar represents 100 mm. (See also
Table S2.)
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pressed slow myosin heavy chain or cTnT, suggesting that the
purity of the obtained population would not be sufficient for
use in large-animal models. With the differentiation protocol
(Zhang et al., 2012) used here, 68% of the differentiated cells ex-756 Cell Stem Cell 15, 750–761, December 4, 2014 ª2014 Elsevier Inpressed cTnT, and the purity was subsequently increased to
>90%viamicrodissection and preplating, yielding a total of three
to four million hiPSC-CMs per well. This yield and purity is suffi-
cient for experiments in large animal models and supports the
feasibility of potential clinical trials.c.
Figure 5. The hiPSC-Derived Cardiac Cells Enhance the Angiogenic Response and Inhibit Apoptosis
Vascular density and arteriole density at week 4 after MI were evaluated in sections from the border zone of infarct in the hearts of animals from the (A) Sham, (B)
MI, (C) Patch, (D) CM, (E) CM+EC+SMC, and (F) Cell+Patch groups via immunofluorescent staining for CD31 and SMA; muscle fibers were visualized via cTnT
staining. (G) Vascular density was determined by counting CD31+ vascular structures, and (H) arteriole density was determined by counting vascular structures
that expressed both CD31 and SMA. *p < 0.05; scale bar represents 200 mm.
(I–N) hiPSC-CMs were cultured under hypoxic conditions in (I) basal media (Basal MEM) or (J) media collected from the hiPSC-derived vascular cells
(Conditioned MEM) for 48 hr; then, (K and L) apoptotic cells were identified via the TUNEL assay, (M) cytotoxicity was quantified via the intensity of
lactate dehydrogenase fluorescence observed in the media, and (N) apoptosis was quantified as the percentage of cells that were positive for TUNEL staining.
*p < 0.05 versus basal MEM; magnification: 1003 for (I) and (J); scale bar represents 100 mm. Data are presented as mean ± SEM. (See also Figure S5 and
Table S2.)
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therapy is the low proportion of transplanted cells that survive
in the recipient heart a few weeks after transplantation (Beau-
champ et al., 1999; Qu et al., 1998; Tang et al., 2010; Zeng
et al., 2007). Coadministration of a cytoprotective agent, such
as IGF-1, can improve cell survival rate (Davis et al., 2006; Li
et al., 1997; Wang et al., 1998), but the administered cells may
still be lost after reestablishment of blood flow or be forced out
of the myocardium along the needle track by high pressure dur-
ing systolic contraction. Notably, a considerably higher rate of
engraftment was observed in hearts from the Cell+Patch group,
which was 2-fold greater than the rate observed in Cell group
hearts, 2.5-fold greater than observed in CMs hearts, and
4-fold greater than when only hiPSC-derived ECs and SMCsCellwere incorporated into a growth-factor-enriched patch (Shimizu
et al., 2002; Xiong et al., 2013). This can be partially attributed to
the fibrin patch itself, as the patch forms a physical barrier pre-
venting ejection of the cells into the epicardial space while
providing a prolonged IGF-1 supply to promote cell survival.
The overall engraftment rate for the three cell populations
administered toCell+Patch animalswas9%and the proportion
of cells that expressed EC-, SMC-, or CM-specific markers are
34%,40%, and27%, respectively. Substantial engraftment
of stem cell-derived CMs has also been observed in a primate
model of postinfarction LV remodeling (Chong et al., 2014):
2% of the LV was composed of engrafted cells, but the
precise engraftment rate could not be calculated because the en-
grafted cells were not counted. However, macaque hearts areStem Cell 15, 750–761, December 4, 2014 ª2014 Elsevier Inc. 757
Figure 6. Protein Expression Levels Are
Significantly Altered in MI and Partially
Restored by Cell Transplantation
Myocardial protein expression profiles were eval-
uated in animals that had been treated with
(MI+iPSC-VC) or without (MI) hiPSC-VC trans-
plantation after experimentally inducedMI; control
assessments were performed in animals that un-
derwent all surgical procedures for the induction of
MI except for the ligation step (SHAM); results are
displayed for 25 proteins whose expression levels
(A) increased or (B) decreased after MI and were
restored to normal levels by cell therapy. NELF-A,
negative elongation factor A; TCEA1, transcrip-
tion elongation factor A protein 1; PF4, platelet
factor 4; ALDH, aldehyde dehydrogenase (mito-
chondrial); SEC22b, vesicle-trafficking protein
SEC22b; LACS6, long-chain-fatty-acid-CoA
ligase 6; RBP4, retinol-binding protein 4; PRDX5,
peroxiredoxin-5 (mitochondrial); SEPT11, septin-
11; SEPT7, septin-7; ecSOD, extracellular super-
oxide dismutase (Cu-Zn); UGPGDH, UDP-
glucose-6-dehydrogenase; PFN2, profiling-2;
UBA-3, NEDD8-activating enzyme E1 catalytic
subunit; UGGT1, UDP-glucose:glycoprotein glu-
cosyltransferase 1; PP2A B56-ε, serine/threonine-
protein phosphatase 2A 56 kDa regulatory subunit
ε isoform; COX4I1, cytochrome C oxidase subunit
4 isoform 1, mitochondrial; NDUFA9, NADH de-
hydrogenase (ubiquinone) 1 a subcomplex sub-
unit 2; HDHPR, dihydropteridine reductase;
RPS25, 40S ribosomal protein S25; GS, glutamine
synthetase; IMPD2, inosine-50-monophosphate
dehydrogenase 2; GMPS, GMP synthase (gluta-
mine-hydrolyzing); COPS3, COP9 sinalosome
complex subunit 3; HScB, iron-sulfur cluster co-
chaperone protein HScB (mitochondrial). Data are
presented as mean ± SEM. (See also Figures S6
and S7.)
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versus 300 g), which contain approximately three billion CMs,
and 70% of cardiac mass is contained in the LV; thus, the
LVs of the animals used in the primate study probably contained
350million CMs, approximately sevenmillion of which (i.e., 2%
of 350 million) were the transplanted hESC-CMs. Since one
billion hiPSC-CMs were administered to each macaque, the
engraftment rate appears to have been 0.7%, which is consis-
tent with other rates reported in the literature (Zeng et al., 2007)
and 10-fold lower that the rate of hiPSC-CM engraftment
observed in the Cell+Patch animals in the present study.
One of the most critical concerns associated with cardiac cell
therapy is the development of arrhythmogenic complications.
The study by Chong et al. (2014) illustrates that transplantation
of humanCMs to large animal post-MImodels can unmaskpoten-
tial arrhythmic complications that are not observed in comparable
small animal models (Shiba et al., 2012). All the monkeys studied
by Chong et al. (2014) that received hESC-CMs developed spon-
taneous arrhythmia during the EKG follow-up evaluations. In the
present study, we used a strategy of a smaller cell dose and aim-
ing at mobilization of the endogenous cardiac progenitors, which758 Cell Stem Cell 15, 750–761, December 4, 2014 ª2014 Elsevier Inwe have reported earlier (Zeng et al., 2007; Xiong et al., 2013). We
used a 100-fold lower dose of hiPSC-CMs compared to Chong’s
report and found no increase of spontaneous or PES-induced
arrhythmia in any of the animals that received cell therapy. The
remarkably better electrical stability achieved with our approach
may be attributable, in part, to the smaller cell dose used (ten
million versus one billion) and targeting the cytokine-associated
mobilization of the endogenous progenitors (Xiong et al., 2013;
Zeng et al., 2007). Electromechanical connectivity may be more
extensive between native tissues and tissues generated through
endogenous repair mechanisms than between native tissues
and large piece of cardiac tissue that develop directly from the
engrafted cells. Coadministration of ECs has been linked to the
regulation of cardiovascular physiology (Brutsaert, 2003; Hsieh
et al., 2006) and could have further improvedmyocardial recovery
primarily through the enhancement of cytokine-associated mech-
anisms. These data also indicate that strategies designed to pro-
mote the paracrine effect of transplanted CMs and ECsmaybe be
more desirable in cardiac cell therapy.
Transplantation of hiPSC-derived cells was also associated
with increases in theexpressionofNkx2.5 inhostcardiomyocytes,c.
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(Toko et al., 2002). Furthermore, myocardial perfusion is main-
tained by the regulatory activity of small resistant vessels (Frame
and Sarelius, 1993), so the significant increase inmyocardial arte-
riole density observed in the BZ of Cell+Patch-treated hearts also
probably contributed todeclines in apoptosis and to the preserva-
tion of contractile function. The increase in arteriole density ap-
pears to have occurred through the sprouting of preexisting
microvessels in the BZ of the treated hearts, because nearly all
of the vesselswereGFP negative. The increase in arteriole density
was also accompanied by a significant improvement in the
myocardial ATP turnover rate (Figure 3F). The calculated rate,
which incorporates the rates associated with all enzymatic pro-
cesses that support contraction and relaxation aswell as the rates
generated by rapid near-equilibrium enzymes, was markedly
reduced at the BZ of infarction in MI hearts, while measurements
under high workload conditions were significantly greater in Cell+
Patch animals than in animals from either the MI or Patch group.
Cyclosporine was administered to animals from all treatment
groups to reduce the likelihood of immune rejection in animals
treatedwith the hiPSC-derived cells. Nevertheless, assessments
of CD11b+ cell density suggest that the immune response was
both elevated and delayed in Patch, CM, CM+EC+SMC, and
Cell+Patch animals (though the increase was significant in only
the Cell+Patch group). Both the patch and the transplanted cells
could have contributed to this increase, because the patch was
created by combining fibrin with thrombin, which is known to
amplify the inflammation induced by ischemia (Chen and
Dorling, 2009), and because the transplanted cells released
inflammatory cytokines such as MCP-1 and IL-6. Notably, IL-6
production was 8-fold and 20-fold higher in hiPSC-ECs than in
hiPSC-CMs or hiPSC-SMCs, respectively. Future study may
be required to find an optimal dosage of cyclosporine or addition
of other immunosuppression regimen, such as FK506, to
minimize the immune rejection and achieve higher cell engraft-
ment rate.
In conclusion, the studies described in this report evaluate the
combined use of hiPSC-ECs, hiPSC-SMCs, and hiPSC-CMs in a
porcine model of ischemia reperfusion myocardial injury. Our re-
sults demonstrate that when the enhanced cell delivery was
achieved by an IGF-1-containing fibrin patch, the engraftment
rate was remarkably greater than achieved with any other deliv-
ery method used in the porcine IR model (Zeng et al., 2007).
Furthermore, the combination of all three cell types with
extended, patch-mediated IGF-1 administration was associated
with significant improvements in myocardial wall stress,
apoptosis, arteriole density, metabolism, and contractile func-
tion. Collectively, these observations support the feasibility of
future mechanistic studies of hiPSC-derived cardiac cells in
large animal models. Studies with longer follow-up periods will
also be needed to ensure that the benefits of treatment aremain-
tained and to fully characterize any potential adverse effects that
may be associated with this promising therapeutic modality.EXPERIMENTAL PROCEDURES
Generation and Characterization of hiPSC-Derived Cardiac Cells
The hiPSC-CMs, hiPSC-SMCs, and hiPSC-ECs used in this study were gener-
ated from two hiPSC lines: DriPS16 (Cell+Patch group) and GRiPS (for the CMCelland CM+EC+SMC groups). Both hiPSC lines were reprogrammed from male,
human, neonatal, dermal fibroblasts by transfecting cells with either lentivirus
(DriPS16) or Sendai virus (GRiPS) coding for OCT4, SOX2, KLF4, and C-MYC
and then engineered to constitutively express GFP. Cells were cultured in
hiPSC growth medium with irradiated mouse embryonic fibroblasts and
passaged every 6–7 days (Wilber et al., 2007).
hiPSCs were differentiated into ECs and SMCs as described previously (Hill
et al., 2010; Woll et al., 2008). hiPSC-ECs were characterized via the expres-
sion of CD31, CD144, and vWF-8 (Xiong et al., 2012). hiPSC-SMCs were char-
acterized via the expression of a-smooth muscle actin (SMA), SM22, and
calponin.
In vitro cytoprotection assays are detailed in Supplemental Experimental
Procedures
Paracrine Factor Release fromCultured hiPSC-CMs, ECs, and SMCs
hiPSC-CMs (3.5 3 105) and hiPSC-SMCs (3.5 3 105) were cultured in 6-well
plates, washed three times with DPBS, and then cultured in 1 ml RPMI basal
medium; hiPSC-ECs (4 3 105) were cultured in 1 ml EBM2 basal medium.
Themediumwas collected 48 hr later and analyzed with the Human Angiogen-
esis Antibody Array G1 Array (RayBiotech). Measurements were corrected for
background signals via control assessments with basal media that had been
exposed to identical conditions.
Synthesis of IGF-containing microspheres and patch manufacture are
detailed in Supplemental Experimental Procedures.
Porcine IR Injury Model and Treatment
Experiments were performed in female Yorkshire swine (13 kg, 45 days of
age, Manthei hog farm, Elk River, MN) (Xiong et al., 2012). The experimental
protocol was approved by the IACUC of the University of Minnesota, and all
experimental procedures were performed in accordance with the Animal
Use Guidelines of the University of Minnesota and consistent with the National
Institutes of HealthGuide for the Care andUse of Laboratory Animals (NIH pub-
lication No 85-23).
A total of 108 pigs underwent the ischemia reperfusion (IR) protocol (Table
S1). Ninety-two pigs were used in the first part of the study: two pigs died of
ventricular fibrillation during occlusion, and one died of cardiac arrhythmia
1 week after IR injury while the MRI data were being collected. The remaining
89 pigs were divided into six groups. Animals in the CM+EC+SMC and
Cell+Patch groups were treated by injecting two million hiPSC-CMs, two
million hiPSC-ECs, and two million hiPSC-SMCs (six million cells total) directly
into the injured myocardium; for animals in the Cell+Patch group, the needle
was inserted through an IGF-1-containing fibrin patch that had been created
over the site of injury. Animals in the Patch group were treated with the patch
alone, and both the patch and the cells were withheld from animals in the MI
group. Animals in the SHAM group underwent all surgical procedures for the
induction of IR injury except for the ligation step and recovered without any
of the experimental treatments. Sixteen pigs were used in loop recorder study.
The Patch+CMgroup used in the arrhythmogenesis experiments exposed to a
protocol of fibrin patch enhanced delivery of ten million hiPSC-CMs on surface
of the injured myocardium (Table S1).
Patch application was performed by suspending 5 mg of microspheres
(loaded with 2.5 mg IGF-1) in 1 ml fibrinogen solution (25 mg/ml); then, the
fibrinogen solution was coinjected with 1 ml thrombin solution (80 NIH units/
ml, supplemented with 2 ml 400 mM CaCl2 and 200 mM Ɛ-aminocaproic
acid) into a 2.3-cm-diameter plastic ring that had been placed on the epicar-
dium of the infarcted region to serve as a mold for the patch; the mixture usu-
ally solidifiedwithin 30 s (Xiong et al., 2012). Cells were suspended in 1mlMEM
and administered via ten intramyocardial injections (0.1 ml/injection).
Cardiac MRI and MR Spectroscopy are detailed in Supplemental Experi-
mental Procedures
The ECG Monitoring and Programmed Electrostimulation
Physiology Studies
The implantable loop recorders (Medtronic-Reveal) were placed in the left par-
aspinal area inferior to the angle of the scapula in the subcutaneous plane. It
was sutured in the place where the best electrograms were obtained and
there was no evidence of myopotential noise. It was programmed in the
conventional manner to document VT and asystole. The loop recorder wasStem Cell 15, 750–761, December 4, 2014 ª2014 Elsevier Inc. 759
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hiPSC-Derived Cardiac Cells for Cardiac Repairinterrogated at the time of explantation when the animals were sacrificed
4 weeks after the cell therapy.
The programmed electrostimulation physiology studies (PES study) were
done at the time of sacrifice in 4 weeks. The PES study was done from the
epicardium in an open-chest fashion. The PES study was done from two sites:
one close to the infarct and one remote from the infarct. The study was done
with a Medtronic screw lead in the epicardium and the Bard system was used
for stimulation. It was done at two cycle lengths at 400 ms and 300 ms drive
trains. Four additional stimuli were given till effective refractory period (ERP)
was reached or 160 ms.
hiPSC-EC, hiPSC-SMC, and hiPSC-CM engraftment rate and immunohisto-
chemical evaluations are detailed in Supplemental Experimental Procedures.
Experimental Procedures for proteomics are detailed in Supplemental
Experimental Procedures.
Statistical Analysis
Results are presented as mean ± SEM. Comparisons among groups were
analyzed for significance with one-way ANOVA. A value of p < 0.05 was
considered significant. Results identified as significant via ANOVA were rean-
alyzed with the Tukey correction. Statistical analyses were performed with
SPSS software (version 20).
SUPPLEMENTAL INFORMATION
Supplemental Information includes Supplemental Experimental Procedures,
six figures, two tables, and three movies and can be found with this article
online at http://dx.doi.org/10.1016/j.stem.2014.11.009.
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